Sugi Predict

Sugi Predict / Compounds / Nafamostat

Nafamostat

Nafamostat

SCHEMBL29429443

N=C(N)Nc1ccc(C(=O)Oc2ccc3cc(C(=N)N)ccc3c2)cc1

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRSS1 P07477 10/20 0.64
▸ PLG P00747 9/20 0.64
▸ F2 P00734 8/20 0.64
▸ F12 P00748 6/20 0.64
▸ KLK1 P06870 3/20 0.64
▸ C1R P00736 2/20 0.64
▸ F10 P00742 2/20 0.64
▸ HGFAC Q04756 2/20 0.64
▸ TMPRSS2 O15393 1/20 0.64
▸ MLNR O43193 1/20 0.64
▸ ALDH1A1 P00352 1/20 0.64
▸ LMNA P02545 1/20 0.64
▸ ITGB3 P05106 1/20 0.64
▸ HPN P05981 1/20 0.64
▸ CHRM2 P08172 1/20 0.64
▸ ITGA2B P08514 1/20 0.64
▸ C1S P09871 1/20 0.64
▸ ADORA3 P0DMS8 1/20 0.64
▸ MAPT P10636 1/20 0.64
▸ CHRM1 P11229 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nafamostat SCHEMBL29429445 1.00 PRSS1 (0.64) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL16069975 1.00 PRSS1 (0.64) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL135503 1.00 PRSS1 (0.64) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL3302794 0.99 PRSS1 (0.63) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL7345508 0.97 PRSS1 (0.62) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL874941 0.94 FTO (0.64) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL7051240 0.94 PLAU (0.58) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL1568755 0.94 FTO (0.70) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL564665 0.94 FTO (0.70) PRSS1PLGF2F12KLK1
Nafamostat SCHEMBL29832433 0.94 FTO (0.70) PRSS1PLGF2F12KLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4149552-A1 COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG Healion Bio, Inc. (US) 2023-03-22 — — EP claimed
CN-115315443-A anti-SARS-COV-2 antibodies and uses thereof 腾盛华创医药技术(北京)有限公司 2022-11-08 — — CN claimed
WO-2022215899-A1 SUSTAINED-RELEASE LIPID PRE-CONCENTRATE 주식회사 티온랩테라퓨틱스 2022-10-13 — — WO claimed
US-20220281939-A1 MODIFIED TFF2 POLYPEPTIDES Tonix Pharmaceuticals, Inc. 2022-09-08 — — US claimed
EP-4021479-A2 MODIFIED TFF2 POLYPEPTIDES Tonix Pharma Limited (IE) 2022-07-06 — — EP claimed
EP-1931320-B1 MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME FLAMEL IRELAND LTD (IE) 2022-06-15 — — EP claimed
WO-2022091065-A1 NOVEL COCRYSTAL, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR (주)아이엠디팜 2022-05-05 — — WO claimed
WO-2022080798-A1 CONTROLLED RELEASE FORMULATION CONTAINING NAFAMOSTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND METHOD FOR PREPARING SAME 뉴지랩테라퓨틱스 주식회사 2022-04-21 — — WO claimed
WO-2022065789-A1 ORAL FORMULATION COMPRISING NAFAMOSTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (주)아이엠디팜 2022-03-31 — — WO claimed
WO-2022065860-A1 INHALABLE FORMULATION COMPRISING NAFAMOSTAT OR CAMOSTAT 충북대학교 산학협력단 2022-03-31 — — WO claimed
US-12274691-B2 Envenomation therapies and related pharmaceutical compositions, systems and kits OPHIREX, INC (US) 2025-04-15 — — US disclosed
EP-4491193-A2 ANTI-CD154 ANTIBODIES AND USES THEREOF Tonix Pharma Limited (IE) 2025-01-15 — — EP disclosed
EP-3993876-B1 ANTI-CD154 ANTIBODIES AND USES THEREOF TONIX PHARMA LTD (IE) 2024-08-28 — — EP disclosed
CN-118510771-A IRAK inhibitors for the treatment of conditions associated with cytokine release associated with respiratory viral infection 里格尔药品股份有限公司 2024-08-16 — — CN disclosed
US-20240058390-A1 WNT+ ADIPOCYTES, EXOSOMES FROM WNT+ ADIPOCYTES, AND METHODS OF MAKING AND USING THEM THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2024-02-22 — — US disclosed
WO-2022091065-A1 NOVEL COCRYSTAL, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR (주)아이엠디팜 2022-05-05 — — WO disclosed
WO-2022080798-A1 CONTROLLED RELEASE FORMULATION CONTAINING NAFAMOSTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND METHOD FOR PREPARING SAME 뉴지랩테라퓨틱스 주식회사 2022-04-21 — — WO disclosed
WO-2022065789-A1 ORAL FORMULATION COMPRISING NAFAMOSTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (주)아이엠디팜 2022-03-31 — — WO disclosed
WO-2022065860-A1 INHALABLE FORMULATION COMPRISING NAFAMOSTAT OR CAMOSTAT 충북대학교 산학협력단 2022-03-31 — — WO disclosed
WO-2022038409-A1 NANOPARTICLES COMPRISING GLYCYRRHIZIN AND WATER-SOLUBLE DRUG, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHODS THEREFOR 주식회사 모든바이오 2022-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12274691-B2 Envenomation therapies and related pharmaceutical compositions, systems and kits PLA2R1, PLA2G12A, ACHE PRSS1 70/4885PLG 27/4885F2 196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.